Darmstadt, Germany, April 18, 2018 — Merck, a leading science and technology company, today announced that its Millistak+® HC Pro portfolio has won an INTERPHEX Exhibitor Award for Best Technological Innovation.
“Merck is dedicated to delivering innovations that bring advanced drug therapies to market, faster,” said Andrew Bulpin, head of the Process Solutions business unit, Life Science, at Merck. “As the first fully synthetic depth filters, Merck’s Millistak+® HC Pro portfolio provides as much as twice the filtration capacity as commercial diatomaceous earth (DE)-based benchmarks and offers customers greater productivity and speed with reduced risk. We are honored to be recognized for this advancement in biopharmaceutical manufacturing.”
Merck’s Millistak+® HC Pro portfolio is a family of synthetic depth filters providing cleaner, more consistent depth filtration media than other DE- and cellulose-based filter offerings. Made with entirely synthetic materials, Millistak+® HC Pro filters eliminate naturally derived components from the clarification process, resulting in increased productivity with less flushing.
Merck’s Process Solutions business unit provides the industry’s most comprehensive portfolio of high-quality products and services for biopharmaceutical manufacturing.For biopharmaceutical manufacturers, Merck’s depth filter reduces total organic carbon extractables and pre-use flush volume by 50 percent. The filter also eliminates the potential for beta glucans, which can interfere with limulus amebocyte lysate testing used to detect and quantify bacterial endotoxins. The unparalleled lot-to-lot consistency helps biopharmaceutical manufacturers design a more robust clarification process.
Merck is showcasing this industry-leading portfolio at Booth 2841 at INTERPHEX, which runs through tomorrow at the Javits Center, New York City.
For more information on Merck’s Millistak+® HC Pro, visit www.merckmillipore.com/Millistack+HCPro.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2017, Merck generated sales of €15.3 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.